Publications

CAR-T

Publications

Follicle-stimulating Hormone Receptor is Expressed by Most Ovarian Cancer Subtypes and is a Safe and Effective Immunotherapeutic Target

Breast Cancer Vaccine

Publications

Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer

Ovarian Cancer Vaccine

Publications

Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Mullerian Hormone Receptor II

Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas

Latest News & Events

Dec 4, 2024

Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10

Read More...

Nov 22, 2024

Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Read More...

Nov 18, 2024

Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Read More...